@misc{10498/29411, year = {2022}, month = {12}, url = {http://hdl.handle.net/10498/29411}, abstract = {Laser photocoagulation has been the standard of treatment of ROP for many years. However, since its introduction in 2007, the use of intravitreal injection of anti-VEGF agents has been incorporated to ROP management. Several trials have shown that anti-VEGF drugs (bevacizumab, ranibizumab) may be superior to laser photocoagulation for type I ROP (zone I [any stage with plus disease] or zone I-stage 3 without plus disease)}, publisher = {Elsevier}, keywords = {Retinopathy of prematurity (ROP)}, keywords = {Bevacizumab}, keywords = {Retinopathy of Prematurity}, title = {Intravitreal Bevacizumab for Retinopathy of Prematurity: Another Hit to the Immature Lung?}, doi = {10.1016/j.chest.2022.06.032}, author = {Alonso-Ojembarrena, Almudena and Oulego‑Erróz, Ignacio}, }